# Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy

> **NCT01848457** · PHASE2 · COMPLETED · sponsor: **Children's Hospital of Philadelphia** · enrollment: 13 (actual)

## Conditions studied

- Osteosarcoma
- Nephrotoxicity
- Ototoxicity

## Interventions

- **DRUG:** Pantoprazole
- **DRUG:** High-dose methotrexate infusion duration

## Key facts

- **NCT ID:** NCT01848457
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-01-04
- **Final completion:** 2016-10-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848457, "Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01848457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*